Search clinical trials for: AML newly diagnosed

Total 5612 results

The First Affiliated Hospital of Soochow University

Recruiting

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

Acute Myeloid Leukemia

China
The First Affiliated Hospital of Soochow University

Recruiting

Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

High Risk Acute Myeloid Leukemia | Intermediate Risk Acute Myeloid Leukemia

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | AML
OncoVerity, Inc.

Not yet recruiting

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Leukemia, Myeloid, Acute
Zhongnan Hospital
Shanxi Province Cancer Hospital; Ruijin Hospital; The First Affiliated Hospital... and other collaborators

Recruiting

MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukaemia

China
Princess Maxima Center for Pediatric Oncology
Daiichi Sankyo

Recruiting

CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients (CHIP-AML22/Q)

Acute Myeloid Leukemia in Children

Netherlands
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy

Acute Myeloid Leukemia

China
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML (HO171)

AML, Adult

Netherlands
Princess Maxima Center for Pediatric Oncology
European Commission

Recruiting

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

Acute Myeloid Leukemia in Children

Netherlands
The First Affiliated Hospital of Soochow University

Recruiting

VA vs DA for Newly Diagnosed Hig-risk AML

Acute Myeloid Leukemia

China
Servier Affaires Médicales

Recruiting

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Acute Myeloid Leukemia (AML)

Netherlands, Italy, Austria, France
Technische Universität Dresden
AbbVie; University Hospital Heidelberg

Not yet recruiting

Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML (VINCENT)

Acute Myeloid Leukemia

Germany
ZePing Zhou
Guizhou Provincial People's Hospital; Second Xiangya Hospital of Central South... and other collaborators

Recruiting

A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.

Acute Myeloid Leukemia | Venetoclax

China
Hematology department of the 920th hospital

Recruiting

A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients

Acute Myeloid Leukemia

China
Chinese PLA General Hospital

Recruiting

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
The First Affiliated Hospital of Soochow University

Recruiting

Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML

Acute Myeloid Leukemia

China
The First Affiliated Hospital of Xiamen University
Fujian Cancer Hospital; Huizhou Municipal Central Hospital; Chipscreen Biosciences... and other collaborators

Recruiting

VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute | AML Stage, Adult

China
Zhongnan Hospital

Recruiting

An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

UCB (Cord Blood) Microtransplantation in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

China
H. Lee Moffitt Cancer Center and Research Institute
Jazz Pharmaceuticals

Recruiting

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

Acute Myeloid Leukemia

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) | FLT3-mutated Acute Myeloid Leukemia

United States
BioSight Ltd.

Recruiting

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

AML, Adult

United States
Zhujiang Hospital

Recruiting

Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients

Leukemia, Myeloid, Acute

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Newly Diagnosed Acute Myeloid Leukemia (AML)

China
Joshua Zeidner
University of North Carolina, Chapel Hill; Stemline Therapeutics, Inc.

Recruiting

Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents (TAGALONG)

Acute Myeloid Leukemia

United States
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Recruiting

Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML

Core Binding Factor Acute Myeloid Leukemia

China
Alice Mims
National Cancer Institute (NCI)

Recruiting

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

Acute Myeloid Leukemia

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The First Affiliated Hospital of Nanchang University; Guangzhou First People... and other collaborators

Recruiting

Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children (SCCLG-M5)

Leukemia, Monocytic, Acute | Pediatric AML

China
The First Affiliated Hospital of Soochow University

Recruiting

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

AML | MDS | Old Age; Debility | Hematologic Cancer

China
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

Acute Myeloid Leukemia, Adult

China
Hospital Universitario Dr. Jose E. Gonzalez

Recruiting

Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis

AML | Hyperleukocytosis

Mexico
Syros Pharmaceuticals

Recruiting

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML

Acute Myeloid Leukemia

United States, France
Shanghai Jiao Tong University School of Medicine

Not yet recruiting

A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy

Leukemia, Myeloid, Acute
PETHEMA Foundation

Recruiting

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Leukemia, Myeloid, Acute | De Novo | Age More 60yr

Spain
University of Ulm
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Germany
Celularity Incorporated

Recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01)

Neoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Hematologic Neoplasms | Physiological Effects of Drugs | Peripheral Nervous System Agents | Analgesics | Analgesics, Non-narcotic | Antimetabolites, Antineoplastic | Leukemia in Remission | Relapsed... and other conditions

United States
Sun Yat-sen University

Not yet recruiting

Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

Acute Myeloid Leukemia | Elderly Patients | Newly Diagnosed

China
University of California, Irvine
Pfizer; Jazz Pharmaceuticals

Recruiting

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Acute Myelogenous Leukemia (AML) Due to Therapy

United States
University of Ulm
Jazz Pharmaceuticals

Recruiting

Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Acute Myeloid Leukemia

Austria, Germany
Stichting Hemato-Oncologie voor Volwassenen Nederland
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Australia, Austria, Belgium, Estonia, Finland, France, Germany, Ireland, Lithuania, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland
Novartis Pharmaceuticals

Recruiting

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

FLT3-mutated Acute Myeloid Leukemia

Korea, Republic of, Germany, Italy, Turkey, Czechia, Jordan, Slovenia, Austria, Poland, Japan, Russian Federation, United States, Greece
Arog Pharmaceuticals, Inc.

Recruiting

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Newly Diagnosed FLT3 Mutated AML

United States
Gesellschaft fur Medizinische Innovation - Hamatologie...

Recruiting

National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup

Newly-diagnosed APL (de Novo or Therapy-related) | Relapsed APL

Germany
St. Jude Children's Research Hospital

Active, not recruiting

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Karyopharm Therapeutics Inc

Active, not recruiting

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Acute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDS

United States, France, Canada, Spain, China
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States, Japan, Taiwan, Spain, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Poland, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Acute Myeloid Leukemia

Italy, Hong Kong, Israel, Hungary, Turkey, Malaysia, United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Acute Myeloid Leukemia

United States, Canada, Puerto Rico, Australia
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)

Leukemia, Myeloid, Acute | Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS)

Spain, United States, France, Korea, Republic of, Taiwan, Australia, Canada, Germany, China, Italy, Austria, Czechia, Poland, Japan, United Kingdom, Russian Federation, Netherlands, Brazil, Israel, Mexico
Novartis Pharmaceuticals

Completed

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

Acute Myeloid Leukemia

Italy, Croatia, Estonia, Czechia, France, Spain, Sweden, Bulgaria, Lithuania, Serbia, Hungary, Finland, Norway, Romania, Slovakia
Uwe Platzbecker
Gilead Sciences

Withdrawn

Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS (MAGROLIC)

Acute Myeloid Leukemia | Myelodysplastic Neoplasm

Search clinical trials for: AML newly diagnosed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations